Why the study?
Are higher von Willebrand factor (VWF) levels associated with increased coronary plaque burden in CAD patients already treated with statins?
Population
91 patients with coronary artery disease undergoing percutaneous coronary intervention under intravascular…
Design
Cross-sectional
Authors
Loading...
Higher VWF linked to greater plaque burden on IVUS despite statins; leaves open its role as marker or target.
Are higher von Willebrand factor (VWF) levels associated with increased coronary plaque burden in CAD patients already treated with statins?
In statin-treated CAD patients, higher VWF levels correlate with increased coronary plaque burden, suggesting VWF may serve as a marker for residual cardiovascular risk.
Kato et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: